User:Mr. Ibrahem/Pemigatinib

Mr. Ibrahem/Pemigatinib
Clinical data
Trade names	Pemazyre
Other names	INCB054828
AHFS/Drugs.com	Monograph
MedlinePlus	a620028
License data	EU EMA: by INN; US DailyMed: Pemigatinib;
Routes of; administration	By mouth
Drug class	Kinase inhibitor
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(morpholin4-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;
Chemical and physical data
Formula	C24H27F2N5O4
Molar mass	487.508 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5;
	InChI InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28); Key:HCDMJFOHIXMBOV-UHFFFAOYSA-N;

Pemigatinib, sold under the brand name Pemazyre, is a medication used to treat bile duct cancer (cholangiocarcinoma).^[1]^[2] It is used in cases which are FGFR2 positive and have failed other treatments.^[2]^[3] It is taken by mouth.^[2]

Common side effects include high or low phosphate, hair loss, diarrhea, tiredness, taste disturbances, inflammation of the mouth, dry eyes, rash, and kidney problems.^[2] Other side effects may include eye problems.^[1] Use in pregnancy may harm the baby.^[1] It is a kinase inhibitor and works by blocking fibroblast growth factor receptors.^[2]^[1]

Pemigatinib was approved for medical use in the United States in 2020.^[1] It received conditional approval in Europe in 2021.^[2] In the United States it costs about 17,800 USD every three weeks.^[4] In the United Kingdom this amount costs the NHS about £7200.^[5]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Pemazyre- pemigatinib tablet". DailyMed. Archived from the original on 6 February 2021. Retrieved 1 February 2021.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Pemazyre EPAR". European Medicines Agency (EMA). 25 January 2021. Archived from the original on 2 September 2021. Retrieved 1 September 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Cite error: The named reference AHFS2021 was invoked but never defined (see the help page).
^ "Pemazyre Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 27 October 2021.
^ "Pemigatinib". SPS - Specialist Pharmacy Service. 11 June 2019. Archived from the original on 27 October 2021. Retrieved 27 October 2021.

[PI2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Pemazyre- pemigatinib tablet". DailyMed. Archived from the original on 6 February 2021. Retrieved 1 February 2021.

[EPAR2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Pemazyre EPAR". European Medicines Agency (EMA). 25 January 2021. Archived from the original on 2 September 2021. Retrieved 1 September 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[AHFS2021-3] Cite error: The named reference AHFS2021 was invoked but never defined (see the help page).

[4] "Pemazyre Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 27 October 2021.

[5] "Pemigatinib". SPS - Specialist Pharmacy Service. 11 June 2019. Archived from the original on 27 October 2021. Retrieved 27 October 2021.

[1]

[2]

[3]

[4]

[5]